XEN 2174

Drug Profile

XEN 2174

Alternative Names: XEN-2174

Latest Information Update: 08 Sep 2015

Price : $50

At a glance

  • Originator Xenome
  • Class Analgesics; Peptides
  • Mechanism of Action Adrenergic uptake inhibitors; Catecholamine plasma membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer pain; Postoperative pain

Most Recent Events

  • 04 Sep 2012 Discontinued - Phase-I for Postoperative pain (in volunteers) in Australia (IV)
  • 04 Sep 2012 XEN 2174 is still in phase I/II development for Cancer pain
  • 01 Aug 2012 Xenome completes a phase II trial in Postoperative pain in Bulgaria (EudraCT2010-019109-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top